Table 2.
Recent/current/pending clinical trials of herpes simplex vaccines.
| Sponsor | Intervention | Summary | Status | ClinicalTrials.gov Identifier |
|---|---|---|---|---|
| Sanofi Pasteur | SP0148 (also known as ACAM 529 or HSV 529), a defective replication HSV-2 with deletions in UL5 and UL29 | Estimated enrollment of 381 HSV-2 seropositive patients | Active, not recruiting; Phase 1/2 | NCT04222985 |
| Genocea Biosciences | GEN-003 is a subunit vaccine comprising HSV-2 glycoprotein D2 (gD2ΔTMR340–363) and infected cell polypeptide 4 (ICP4383–766) adjuvanted with proprietary Matrix-M2 | Genocea Biosciences, Inc. announced that they entered into a material transfer agreement and exclusive license option with Shionogi & Co., Ltd. | Terminated; Phase 2 |
NCT03146403 |
| Vical | VCL-HB01 Plasmid-based vaccine encoding two HSV-2 proteins and VCL-HM01 Plasmid-based vaccine encoding one HSV-2 protein, both adjuvanted with Vaxfectin | VCL-HB01 was ineffective in reducing outbreaks in people who were infected with HSV-2 | Completed; Phase 2 |
NCT02837575 |
| Agenus | HerpV polyvalent peptide complex adjuvanted with QS-21 | Stopped after Phase 2 | Completed; Phase 2 |
NCT01687595 |
| X-Vax Technology | HSV-2 ΔgD-2 | Preparing for a Phase 1 clinical study | Preclinical | NA |
| UPenn in collaboration with BioNTech | HSV-2 mRNA vaccine coding gC2, gD2, and gE2 | Preparing for a Phase 1 clinical study | Preclinical | NA |
| Rational Vaccines | RVx201 (derivative of HSV-2 0∆NLS) | Preparing for a Phase 1 clinical study | Preclinical | NA |
| Rational Vaccines | RVx1001 (HSV-1 VC2) | Preparing for a Phase 1 clinical study | Preclinical | NA |